Yasuhiro Tsume1, Gordon L Amidon. 1. College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065, USA.
Abstract
PURPOSE: To determine the correlations/discrepancies of drug stabilities between in the homogenates of human culture cells and of human tissues. METHODS: Amino acid/dipeptide monoester prodrugs of floxuridine were chosen as the model drugs. The stabilities (half-lives) of floxuridine prodrugs in human tissues (pancreas, liver, and small intestine) homogenates were obtained and compared with ones in cell culture homogenates (AcPC-1, Capan-2, and Caco-2 cells) as well as human liver microsomes. The correlations of prodrug stability in human small bowel tissue homogenate vs. Caco-2 cell homogenate, human liver tissue homogenate vs. human liver microsomes, and human pancreatic tissue homogenate vs. pancreatic cell, AsPC-1 and Capan-2, homogenates were examined. RESULTS: The stabilities of floxuridine prodrugs in human small bowel homogenate exhibited the great correlation to ones in Caco-2 cell homogenate (slope = 1.0-1.3, r2 = 0.79-0.98). The stability of those prodrugs in human pancreas tissue homogenate also exhibited the good correlations to ones in AsPC-1 and Capan-2 cells homogenates (slope = 0.5-0.8, r2 = 0.58-0.79). However, the correlations of prodrug stabilities between in human liver tissue homogenates and in human liver microsomes were weaker than others (slope = 1.3-1.9, r2 = 0.07-0.24). CONCLUSIONS: The correlations of drug stabilities in cultured cell homogenates and in human tissue homogenates were compared. Those results exhibited wide range of correlations between in cell homogenate and in human tissue homogenate (r2 = 0.07 - 0.98). Those in vitro studies in cell homogenates would be good tools to predict drug stabilities in vivo and to select drug candidates for further developments. In the series of experiments, 5'-O-D-valyl-floxuridine and 5'-O-L-phenylalanyl-L-tyrosyl-floxuridine would be selected as candidates of oral drug targeting delivery for cancer chemotherapy due to their relatively good stabilities compared to other tested prodrugs.
PURPOSE: To determine the correlations/discrepancies of drug stabilities between in the homogenates of human culture cells and of human tissues. METHODS: Amino acid/dipeptide monoester prodrugs of floxuridine were chosen as the model drugs. The stabilities (half-lives) of floxuridine prodrugs in human tissues (pancreas, liver, and small intestine) homogenates were obtained and compared with ones in cell culture homogenates (AcPC-1, Capan-2, and Caco-2 cells) as well as human liver microsomes. The correlations of prodrug stability in human small bowel tissue homogenate vs. Caco-2 cell homogenate, human liver tissue homogenate vs. human liver microsomes, and humanpancreatic tissue homogenate vs. pancreatic cell, AsPC-1 and Capan-2, homogenates were examined. RESULTS: The stabilities of floxuridine prodrugs in human small bowel homogenate exhibited the great correlation to ones in Caco-2 cell homogenate (slope = 1.0-1.3, r2 = 0.79-0.98). The stability of those prodrugs in humanpancreas tissue homogenate also exhibited the good correlations to ones in AsPC-1 and Capan-2 cells homogenates (slope = 0.5-0.8, r2 = 0.58-0.79). However, the correlations of prodrug stabilities between in human liver tissue homogenates and in human liver microsomes were weaker than others (slope = 1.3-1.9, r2 = 0.07-0.24). CONCLUSIONS: The correlations of drug stabilities in cultured cell homogenates and in human tissue homogenates were compared. Those results exhibited wide range of correlations between in cell homogenate and in human tissue homogenate (r2 = 0.07 - 0.98). Those in vitro studies in cell homogenates would be good tools to predict drug stabilities in vivo and to select drug candidates for further developments. In the series of experiments, 5'-O-D-valyl-floxuridine and 5'-O-L-phenylalanyl-L-tyrosyl-floxuridine would be selected as candidates of oral drug targeting delivery for cancer chemotherapy due to their relatively good stabilities compared to other tested prodrugs.
Authors: J L Grem; N Harold; J Shapiro; D Q Bi; M G Quinn; S Zentko; B Keith; J M Hamilton; B P Monahan; S Donavan; F Grollman; G Morrison; C H Takimoto Journal: J Clin Oncol Date: 2000-12-01 Impact factor: 44.544
Authors: Thorir D Bjornsson; John T Callaghan; Heidi J Einolf; Volker Fischer; Lawrence Gan; Scott Grimm; John Kao; S Peter King; Gerald Miwa; Lan Ni; Gondi Kumar; James McLeod; R Scott Obach; Stanley Roberts; Amy Roe; Anita Shah; Fred Snikeris; John T Sullivan; Donald Tweedie; Jose M Vega; John Walsh; Steven A Wrighton Journal: Drug Metab Dispos Date: 2003-07 Impact factor: 3.922
Authors: D J Purifoy; L M Beauchamp; P de Miranda; P Ertl; S Lacey; G Roberts; S G Rahim; G Darby; T A Krenitsky; K L Powell Journal: J Med Virol Date: 1993 Impact factor: 2.327
Authors: Yasuhiro Tsume; Balvinder S Vig; Jing Sun; Christopher P Landowski; John M Hilfinger; Chandrasekharan Ramachandran; Gordon L Amidon Journal: Molecules Date: 2008-06-28 Impact factor: 4.411
Authors: Yongjun Hu; Daniel Epling; Jian Shi; Feifeng Song; Yasuhiro Tsume; Hao-Jie Zhu; Gordon L Amidon; David E Smith Journal: Biochem Pharmacol Date: 2018-08-17 Impact factor: 5.858
Authors: Atheer Zgair; Yousaf Dawood; Suhaib M Ibrahem; Jong Bong Lee; Wanshan Feng; Peter M Fischer; Pavel Gershkovich Journal: Molecules Date: 2021-01-05 Impact factor: 4.411